Research Funding

Funding for research is a high priority for Hemophilia of Georgia.
The agency currently funds six researchers through the Hemophilia Clinical Scientist Development Grant.  And, two additional researchers will be selected this year. Through this program, HoG hopes to help create the next generation of hemophilia researchers.

Hemophilia of Georgia began funding physician researchers in 2003 to conduct translational research on hemophilia and its complications. In 2005, the agency began funding three more researchers. Read about the Research Grantees. 

Each grant is for $75,000 a year, renewable for up to five years, with an additional $7,500 per year for indirect costs.  The grant requires an 80% time commitment to hemophilia-related research.  This funding will allow a physician who has completed research training to advance to the status of an independent investigator. 

Funding for the American Thrombosis and Hemostasis Network 

HoG was a catalyst for the creation of the American Thrombosis and Hemostasis Network (ATHN), a non-profit organization founded to advance and improve the care of individuals affected by bleeding and thrombotic disorders. ATHN’s mission is to provide stewardship of a secure national database, adherent to all privacy guidelines, which will be used to support clinical outcomes analysis, research, advocacy and public health reporting in the hemostasis and thrombosis community. 

Funding for Infectious Disease Research 

Hemophilia of Georgia also provides funding for infectious disease research conducted by Dr. James Steinberg, Dr. Melissa Osborn, and Francie Lasseter, RN of Emory Crawford Long Hospital.  This funding enables them to participate in the Impact of HIV on Hepatitis C in Hemophilia study, a multicenter NIH-funded study spearheaded by Dr. Margaret Ragni at the University of Pittsburgh.  Twenty-seven sites are involved in this study. The Emory group has enrolled the second largest number of patients (over 80).  The purpose of this study is to learn how often people with hemophilia develop cirrhosis from chronic hepatitis C infection and to study the impact of HIV on liver disease.

Dr. Melissa Osborn is analyzing data from the Multicenter Hemophilia Cohort Study II.  She is investigating the impact of antiretroviral therapy on hepatitis C progression.

Dr. Steinberg’s group is involved in translational hepatitis C research studies, partnering with virologists and immunologists at the Emory Vaccine Center.  These researchers, led by Dr. Arash Grakoui, are investigating why some patients clear hepatitis C infection and others progress to advanced liver disease.  About 20 people with hemophilia have provided blood samples for these studies.